Reproductive Factors Associated to Human Papillomavirus Infection in Iranian Woman

Freshteh Jahdi; M.Sc.1, Khadijeh Khademi; M.Sc.1, Effat Merghati Khoel; M.D.2, Hamid Haghani; M.Sc.3, Fariba Yarandi; M.D.4

1 Nursing & Midwifery School, Tehran University of Medical Sciences, Tehran, Iran
2 Public Health School, Tehran University of Medical Sciences, Tehran, Iran
3 Medical Management & Information School, Tehran University of Medical Sciences, Tehran, Iran
4 Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran

Received January 2013; Revised and accepted March 2013

Abstract

Objective: In recent years, human papillomaviruses (HPV) infection is the most common type of sexual transmitted diseases (STD) in majority of countries. It’s a significant source of morbidity and mortality worldwide. In this study, we aimed to compare the history of reproductive disease between two groups of Iranian women with and without HPV infection through colposcopy procedure.

Materials and methods: This case-control study included 210 women referred to a training gynecology hospital of Tehran University of Medical Science in Tehran. Case group was composed of 70 women with diagnosis of HPV infection, while control group was composed of 140 women with no sign of mentioned-infectious diseases of the control group. Reproductive history was prepared using the standard questionnaire, and obtained data were analyzed by SPSS 20.

Results: Our findings showed that the risk factors for HPV infection were as follows: low parity (p = 0.000), reduction of number of weekly sexual intercourse (p = 0.000), no consumption of oral contraceptive pill (OCP) (p = 0.006), and history of withdrawal contraceptive method (p = 0.001).

Conclusion: Improvement of our knowledge about reproductive factors associated with HPV may help us to identify women at risk and to develop different methods of preventive interventions.

Keywords: Sexually Transmitted Diseases (STD), Human Papilloma Virus (HPV), Iranian Women

Introduction

Nowadays, human papilloma virus (HPV) has been known as the most common type of sexually transmitted infection (STI) in the United States (1). It is an important source of morbidity and mortality worldwide, and is also identified as a prerequisite for development of cervical cancer (2). Cervical cancer is the second most common type of cancer worldwide, comprising approximately 12% of all types in women (3). In developing countries, cervical cancer is one out of two causes of mortality in women (4). About 10.0% out of 2329.08 million women aged 15 years or older worldwide, 8.3% out of 265,884 women in Asia and 6.6% out of 24.54 million women in Iran have been estimated to harbour cervical HPV infection at a given time (3). HPV infection may cause a variety of low grade squamous intraepithelial lesions in cervix and benign ones in anogenital areas

Correspondence:
Khadijeh Khademi, Nosrat Ave., Tohid Squ., School of Nursing & Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Email: yaldamohammad4@yahoo.com
known as condylomata acuminata (genital warts) (5). The psychological discomforts and stigma of genital warts, along with the physical discomforts associated with treatment, agonize the patients (6). HPV infection has been associated with high levels of trait anxiety, obsessions, compulsions, and above all, behaviours and worries due to hygiene and improbable infections (7). On other hands, subclinical and clinical HPV infections are responsible for high morbidity and impose a great burden on the health care system, so that it was concluded that cervical HPV-related disease accounted for total healthcare costs of $3.4 billion (8). Many epidemiological studies have supported the association between sexual activity and acquisition of HPV infection, so as the greater the number of sexual partners, the greater the risk of HPV infection (9). For women, sexual activity of their partner(s) is also important for determining the risk of HPV acquisition. Other risk factors associated with HPV infection include history of vulvar warts or infection with herpes simplex viruses (HSV) (10). Age also seems to be an important factor as HPV infection is consistently the most common STD in sexually active women younger than 25 years old (11). The presence of recrudescent chlamydia infections is an important factor for the clinical manifestations of anogenital warts (12). Nevertheless, there has been conflicting evidence that reproductive factors increase the risk of HPV (13). It is important to have a thorough and accurate understanding of the prevalence and risk factors of this infection (14) because this information will be helpful in implementation of future prevention strategies (15). In this study, we aimed to compare the history of reproductive disease between two groups of Iranian women with and without HPV infection through colposcopy procedure.

Materials and methods

After being approved by Scientific Ethics Committee of Tehran University of Medical Sciences (TUMS) in 2012, 210 women were recruited from the outpatient colposcopy clinic belonging to a training gynecology hospital of TUMS. Sampling was done during January to April. Women with an abnormal pap smear test as well as abnormal vaginal bleeding or resistant cervicitis had been referred to this clinic for further investigation. Colposcopy and biopsy of cervical lesion were undertaken for the differential diagnosis.

In this study, inclusion criteria used for selection were as follows: being mentally healthy and being referred to the clinic due to abnormal pap smear test. Case group was composed of 70 women with diagnosis of either condyloma acuminata in biopsy specimen of cervix or positive HPV for types 6, 11, 16, 18, 31, 35, and 50-60, while control group was composed of 140 women with no sign of mentioned-infectious diseases of the control group. Two group were matched according to Iranian-descent, being in reproductive ages (15-49 years) and acquiring LSIL/HPV result in pap smear test. Biopsy specimen of cervix was taken by three gynecology specialists, and the specimen was interpreted by the pathology laboratory of the same gynecology hospital.

After receiving detailed information regarding the objectives of the study, all women signed a written consent form and were asked to complete a self-administered questionnaire. This questionnaire included questions about socio-demographic traits, reproductive and medical history. The validity of questionnaire was performed by 12 members of the Faculty of Nursing & Midwifery School of TUMS. The Test-retest method was used to determine the reliability of the questionnaire and r = 0.85 -1 was calculated.

The statistical analysis was performed using T-test, Chi-square and Fisher exact tests to compare frequencies between groups. Logistic regression models were used to identify marital factors associated independently with HPV infection. The value of p < 0.05 was considered statistically significant. Data analysis was done using SPSS 20.

Results

In this case-control study, 210 women with LSIL/HPV result on pap smear test were participated. The median age of all participated women was 35.052 ± 8.018 years, while the age ranged from 17 to 49 years. Most women in both groups had normal age at menarche (13-14 years). The median number of pregnancy in case group was 1.342 ± 1.371 times, but in control group was 2.328 ± 1.451 times. The median number of delivery in case group was 1.100 ± 1.078 times, while in control group was 2 ± 1.414 times. History of cesarean delivery was observed in 19.5% of cases and 25.4% of controls (only women with delivery history were assessed). None of women in case group had history of induced abortion, but in control group, 19% of women experienced induced abortion. History of infertility was observed in 6.1% of women in case group and
4.3% of women in control group. The median number of sexual intercourse per week in case group was 1.970 ± 1.103 times, while in control group was 1.603 ± 1.153 times. The history of contraceptive methods in cases and controls, respectively, were as follows: Injections of progesterone (5.7%, 4.3%); IUD (11.4%, 15%); T.L (5.7%, 10.7%); OCP (24.3%, 47.9%); withdrawal (71.4%, 54.3%); and condom (45.7%, 36.4%).

None of cases had history of familial cervical cancer, but 6.6% of women in control group reported history of cervical cancer in one of the family members. The characteristics of the study women in relation to HPV infection are reported in table 1.

Our findings showed that pregnancy number (p = 0.000), sexual intercourse number per week (p = 0.000), no consumption of OCP (p = 0.006), history of withdrawal contraceptive method (p = 0.001) were independently associated with HPV infection (Table 1).

**Discussion**

This study was conducted to determine reproductive factors associated to HPV infection in Iranian women. Although HPV infection is the most commonSTD worldwide, factors associated with this infection, except high risk sexual behaviours, are either unknown, or the obtained results are inconsistent (3). Our findings showed reduction in the number of pregnancy associated with HPV infection, which were not in concordance with studies by S. Sukvirach et al. and JA. Kan et al. (16, 17). This conflict can represent differences in cultural context of society about pregnancy trends and interest. In addition, we found reduction of weekly sexual intercourse related to HPV infection, which was not in agreement with study by AN. Burchell, et al. (18). Differences in study method or selected population may lead to inconsistent result. In this study, among contraceptive methods, only withdrawal method was associated with HPV infection, whereas the study of A. Safaei et al. didn’t approve this result (19). They presented that low number of HPV infected women led to an inappropriate conclusion. Although RL. Winer et al. (HR: 1.4, 95% CI: 1.1-1.8), P. Ammatuna et al. (p = 0.03) and Y-L. Qiao et al. (OR ~ 2) found relationship between OCP and HPV positive (13, 20, 21), we found no relationship between these two variables (OR~4). Likely, more use of withdrawal contraceptive method among the cases causes lower consumption of OCP. In addition, there are severl studies from different locations, like the USA, Warsaw, Poland, Govindpuri, and North India, which are in contrast or in concordance with our findings about the other reproductive factors not to be associated with HPV infection (22-24). Distinction in sampling method or limitition of study may be two reasons that cause varied results.

In conclusion, HPV infection and subsequent cervical cancer are considered to be important public health problem worldwide. Some reproductive factors are associated with increasing incidence of this infection. Therefore, improvement of our knowledge about reproductive factors associated with HPV may help us to identify women at risk and to develop different methods of preventive interventions.

We hope that further comprehensive studies will be performed to assess reproductive factors associated with HPV infection in general population of Iranian women. These studies will present a clearer information about HPV infection in order to improve strategies for the prevention and treatment of HPV-associated lesions.

**Acknowledgements**

We gratefully thank the personnel of colposcopy clinic of Tehran University of Medical Science and all women participating in this study. This study was funded and supported by Tehran University of Medical Sciences and from corresponding Author’s thesis. There is no conflict of interest in this article.
Table 1: Associations between HPV infection and reproductive factors in women with HPV/LSIL result on pap test

| Reproductive factors                  | Frequency in group                      | p-value |
|---------------------------------------|-----------------------------------------|---------|
|                                       | Cases (n=70)                             | Controls (n=140) |
| Age at menarche (year)                |                                        |         |
| < 13                                  | 17 (24.3%)                              | 21 (15.0%)      |
| 13-14                                 | 28 (40.0%)                              | 91 (65.0%)      |
| ≥ 15                                  | 25 (35.7%)                              | 28 (20.0%)      |
| Pregnancy number (time)               |                                        | 0.000     |
| 0                                     | 29 (41.4%)                              | 18 (12.9%)      |
| 1                                     | 8 (11.4%)                               | 28 (20.0%)      |
| 2                                     | 21 (30%)                                | 24 (17.1%)      |
| 3                                     | 4 (5.7%)                                | 36 (25.7%)      |
| ≥ 4                                   | 8 (11.4%)                               | 34 (24.3%)      |
| Delivery number (time)                |                                        | 0.000     |
| 0                                     | 29 (41.4%)                              | 26 (18.6%)      |
| 1                                     | 13 (18.6%)                              | 25 (17.9%)      |
| 2                                     | 20 (28.6%)                              | 39 (27.9%)      |
| ≥ 3                                   | 8 (11.4%)                               | 50 (35.7%)      |
| Hx* of cesarean delivery              |                                        |           |
| Yes                                   | 8 (19.5%)                               | 29 (25.4%)      |
| No                                    | 33 (80.5%)                              | 85 (74.6%)      |
| Hx* of induced abortion               |                                        |           |
| Yes                                   | 0 (0.0%)                                | 26 (19.0%)      |
| No                                    | 66 (100.0%)                             | 111 (81.0%)     |
| Hx* of infertility                    |                                        | 0.000     |
| Yes                                   | 4 (6.1%)                                | 6 (4.3%)       |
| No                                    | 62 (93.9%)                              | 134 (95.7%)     |
| Sexual intercourse number (time/week) |                                        | 0.000     |
| ≤ 1                                   | 33 (56.9%)                              | 59 (44.0%)      |
| 2                                     | 12 (20.7%)                              | 38 (28.4%)      |
| 3                                     | 8 (13.8%)                               | 25 (18.7%)      |
| ≥ 4                                   | 5 (8.6%)                                | 12 (9.0%)       |
| Hx of contraception method            |                                        | 0.006     |
| Hx* of progesterone injection         |                                        |           |
| Yes                                   | 4 (5.7%)                                | 6 (4.3%)       |
| No                                    | 66 (94.3%)                              | 134 (95.7%)     |
| Hx* of infertility of IUD             |                                        | 0.000     |
| Yes                                   | 8 (11.4%)                               | 21 (15.0%)      |
| No                                    | 62 (88.6%)                              | 119 (85.0%)     |
| Hx* of T.L**                          |                                        |           |
| Yes                                   | 4 (5.7%)                                | 15 (10.7%)      |
| No                                    | 66 (94.3%)                              | 125 (89.3%)     |
| Hx* of OCP***                         |                                        | 0.006     |
| Yes                                   | 17 (24.3%)                              | 67 (47.9%)      |
| No                                    | 53 (75.7%)                              | 73 (52.1%)      |
| Hx* of withdrawal method              |                                        | 0.001     |
| Yes                                   | 50 (71.4%)                              | 76 (54.3%)      |
| No                                    | 20 (28.6%)                              | 64 (45.7%)      |
| Hx* of condom                         |                                        |           |
| Yes                                   | 32 (45.7%)                              | 51 (36.4%)      |
| No                                    | 38 (54.3%)                              | 89 (63.6%)      |
| Familiar Hx* of CC****                |                                        | 0.006     |
| Yes                                   | 0 (0.0%)                                | 9 (6.6%)       |
| No                                    | 66 (100.0%)                             | 128 (93.4%)     |
References
1. Ammatuna P, Giovannelli L, Matranga D, Ciriminna S, Perino A. Prevalence of Genital Human Papilloma Virus Infection and Genotypes among Young Women in Sicily, South Italy. Cancer Epidemiology, Biomarkers & Prevention 2008:17 : 2002-6.
2. Bhatla N, Datta P, Dar L, Patro AR., Gulati A, Kriplani A, & et al. Prevalence of human papillomavirus infection among young women in North India. Cancer Epidemiology2010; 34: 57-61.
3. Burchell AN, Tellier PP, Hanley J, Coutle FO, Franco EL. Human Papillomavirus Infections Among Couples in New Sexual Relationships. Epidemiology 2010;21 : 31-7.
4. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, et al., editors. HPV and Cervical Cancer in the World: 2007 Report. Vaccine. 2007;25(Suppl 3):c1–c230.
5. Diaz M. LHuman Papilloma Virus – Prevention and Treatment. Obstetrics & Gynecology Clinics of North America 2008;35 : 199-217.
6. Dunne EF, Unger ER, Sternberg M, Mcquillan G, Swan DC, Patel SS, et al. Prevalence of HPV Infection Among Females in the United States. The Journal of the American Medical Association 2007; 297: 813-9.
7. Franceschi S, Bardin A, Vaccareela S, Clifford GM, Lissowska J, Rekosz M, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. European Journal of Cancer 2008;44 : 557-64.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
9. Hager WD. Human Papilloma Virus Infection and Prevention in the Adolescent Population. Journal of Pediatric Adolescent Gynecology 2009;22 : 197-204.
10. Insingo RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus—related disease. Am J Obstet Gynecol 2004; 191: 114-20.
11. Kahn JA, Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. Journal of Clinical Virology2009; 46: 107-11.
12. Kyriakis KP, Hadjivassiliou M, Paparizos VA, Riga P, Katsambas A. Determinants of genital wart case detection rates among STD clinic attendees in Athens, Greece. Int J Dermatol 2005; 44 : 650-3.
13. Maggino T, Casadei D, Panontin E, Fadda E, Zampieri MC, Dona MA, et al. Impact of an HPV diagnosis on the quality of life in young women. Gynecologic Oncology2007; 107: S175-79.
14. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. The Journal of American Medical Association 2001;285: 2995–3002.
15. National Cancer Institute. HPV and cervical cancer. 2012: 1- 5. Available at:http://www.cancer.gov/cancertopics/factsheet/Risk/Fs3_20.pdf.
16. Professional Advisory Board of the Australia and New Zealand HPV Project. Guidelines for the Management of Genital HPV in Australia and New Zealand. 6th ed, 2010: 1-36. Available at : http://www.hpv.org.nz/pdfs/HPV%20Guidelines%202010_FA.pdf
17. Safaei A, Khanlari M, Montmahan M, Monbati A, Robati M, Amooei S, & et al. 2010. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran.Indian Journal of Pathology & Microbiology 53 : 681-5.
18. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al. Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand. The Journal of Infectious Diseases2003; 187:1246- 56.
19. Tchernev G. Sexually transmitted papillomavirus infections: epidemiology, pathogenesis, clinical morphology, important differential diagnostic aspects, current diagnostic and treatment options. Anais Brasileiros de Dermatologia2009; 84: 377-89.
20. Trottier H, Franco EL. Human Papillomavirus and Cervical Cancer: Burden of Illness and Basis for Prevention. The American Journal of Managed Care 2006; 12: S462-72.
21. Wheeler CM. Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities and Cancer. Obstetrics Gynecology Clinics of North America 2008;35: 519-36.
22. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment, and prevention. Clinical Infectious Diseases 2002;35: S210–24.
23. Winer R.L, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsy LA. Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. American Journal of Epidemiology 2003;157: 218-26.
24. World Health Organization. Human papillomavirus and cervical cancer. 2008.Retrieved March 1. Available at:http://www.who.int/immunization/topics/hpv/en.